Emerging studies about patients and experimental models have determined the imbalance between Th17 and Treg cells as well as the related cytokines in the serum, including IL-6, IL-1b, and IL-23, and signal transducer, participated in the onset and progression of autoimmune diseases including SLE (3, 27), immune therapy could restore Treg/Th17 imbalance and thus ameliorate SLE and RA (4, 8, 28–30). This evidence concerns the gene IL6 and systemic lupus erythematosus.